retinal vein occulsion

Clearside enrolls first patient in phase III trial of Zuprata combination therapy
Drug Delivery Business News
Mon, 02/20/17 - 09:53 am
Clearside Biomedical
Zuprata
Eylea
retinal vein occulsion